- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07715851
Survival, Success, Stability, and Patient Comfort of TADs Placed by Steady Oblique-Angled Versus Two-Step Angulation Insertion Techniques
Survival, Success, Stability, and Patient Comfort of Temporary Anchorage Devices Placed by Steady Oblique-Angled Versus Two-Step Angulation Insertion Techniques: A Split-Mouth Randomised Clinical Trial
The goal of this clinical trial is to learn if two-step angulation Temporary Anchorage Devices (TADs) insertion technique better for survival, stability and patient-reported outcomes. It will also learn about how the trabecular bone volume fraction measured from pre-treatment CBCT imaging influences the stability, survival, and overall clinical success of TADs. The clinical trial will be carried out among fit and healthy adults aged 18 years old above who require extraction of all four permanent first premolars, planned for maximum anchorage using bilateral maxillary and mandibular TADs.
The main questions it aims to answer are:
In orthodontic patients,
- does the two-step angulation insertion technique for TADs provide superior survival, stability, and patient-reported outcomes, with acceptable complication rates?
- how are these outcomes influenced by maxillary and mandibular trabecular bone volume fraction measured on CBCT?
Researchers will compare two-step angulation insertion technique to steady oblique-angled TADs insertion technique to see it provide more superior survival, stability, and patient-reported outcomes, with acceptable complication rates.
Participants will:
- be taken CBCT radiography before TADs insertion
- receive both TADs insertion technique either right or left on both maxilla and mandible between second premolars and first molars
- fill up patient reported outcome questionnaire At immediate post-insertion (T0), post alignment (T1), and subsequently at monthly intervals during en-masse retraction: 1 month (T2), 2 months (T3), 3 months (T4), 4 months (T5), 5 months (T6), 6 months (T7)
- visit the clinic for measurement of TADs stability, clinical assessment of inflammation, mobility and the need for replacement at immediate post-insertion (T0), post alignment (T1), and subsequently at monthly intervals during en-masse retraction: 1 month (T2), 2 months (T3), 3 months (T4), 4 months (T5), 5 months (T6), 6 months (T7)
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Wan Ying Lee, Master of Oral Science
- Phone Number: 014-8416384
- Email: 17125177@siswa.um.edu.my
Study Locations
-
-
Kuala Lumpur
-
Kuala Lumpur, Kuala Lumpur, Malaysia, 50603
- Faculty of Dentistry, Universiti Malaya
-
Contact:
- Wan Ying Lee, Master of Oral Science
- Phone Number: 014-8416384
- Email: 17125177@siswa.um.edu.my
-
Principal Investigator:
- Saritha Sivarajan
-
Sub-Investigator:
- Siti Adibah Othman
-
Sub-Investigator:
- Maziahtul Zawani Munshi
-
Principal Investigator:
- Wan Ying Lee
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age range: 18 years old and above
- Bimaxillary proclination with maximum anchorage control with TAD in maxilla and mandible
- Extraction of all four permanent first premolar as part of orthodontic treatment
- Crowding in the upper and lower incisors (< 5.0mm)
- Overjet less than 6mm
- BPE score 0, 1 or 2
- Average vertical facial proportions
Exclusion Criteria:
- Systemic diseases such as diabetes, osteoporosis
- On long term use of antibiotics, phenytoin, cyclosporin, anti-inflammatory drugs, systemic corticosteroid and calcium channel blockers that would affect the bone biology
- Cigarette smoking, vaping, history of smoking
- Impacted / missing teeth at the treatment site
- BPE score 3 and 4
- Vertical skeletal discrepancies e.g. high angle and low angle.
- Orthognathic treatment need
- Craniofacial disorder, cleft lip and palate, syndromes
- Low maxillary sinus level with alveolar crest height of less than 4mm
- Titanium allergy
- Pregnant woman
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Two-step Angulation with Partial Unwinding Technique
This is a split-mouth randomized clinical trial design where each participant serves as their own internal control.
This arm represents the specific jaw quadrants randomized to receive Temporary Anchorage Device (TAD) insertion using a two-step angulation with a partial unwinding technique.
The TAD is first placed parallel to the occlusal plane to create a cortical bone indentation (guided by a rubber depth stopper based on CBCT bone thickness), partially backed out (derotated) by half a turn, and subsequently reangulated to a final seating angle of 30-45 degree relative to the occlusal plane between the second premolar and first permanent molar.
|
The TAD (1.6 mm diameter X 6 mm length; J2, Dual-Top Anchor System, Jeil Medical, Seoul, Korea) will be inserted directly against cortical bone surface at 30-45° to the occlusal plane, targeted anatomically between second premolar and first permanent molar.
The device will be manually driven into the alveolar bone using a manual torque driver calibrated to a 10 Ncm torque value
|
|
Active Comparator: Steady Oblique Angulation Technique
This is a split-mouth randomized clinical trial design where each participant serves as their own internal control.
This arm represents the specific jaw quadrants randomized to receive Temporary Anchorage Device (TAD) insertion via a single-step, steady oblique angulation approach.
The screw is inserted directly into the alveolar bone at a constant angle of 30 to 45 degree relative to the occlusal plane, targeted anatomically between the second premolar and first permanent molar.
|
The TAD (1.6 mm diameter X 6 mm length; J2, Dual-Top Anchor System, Jeil Medical, Seoul, Korea) will be inserted directly against cortical bone surface at 30-45° to the occlusal plane, targeted anatomically between second premolar and first permanent molar.
The device will be manually driven into the alveolar bone using a manual torque driver calibrated to a 10 Ncm torque value
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Survival rate
Time Frame: Post alignment (at the start of enmasse retraction), and subsequently at monthly intervals during en-masse retraction: Month 1, Month 2, Months 3, Month 4, Months 5, Months 6.
|
Survival Rate Percentage of TADs that remain physically retained in bone (not necessarily stable for orthodontic load) over 6 months, regardless of whether they are functionally useful (Schätzle et al., 2009) Citeria of Survived TADs Retain in bone regardless function and complications. Mininum value:0% Maximum value: 100% Higher value indicate greater percentage of TADs that remain physically retained in bone (not necessarily stable for orthodontic load) |
Post alignment (at the start of enmasse retraction), and subsequently at monthly intervals during en-masse retraction: Month 1, Month 2, Months 3, Month 4, Months 5, Months 6.
|
|
Success rate
Time Frame: at immediate post-insertion (Day 0), post alignment (at the start of en-masse retraction), and subsequently at monthly intervals during en-masse retraction: Month 1, Month 2, Month 3, Month 4, Month 5, and Month 6.
|
Success Rate Percentage of TADs that remain functionally stable and serve their orthodontic purpose throughout treatment, without mobility, infection, or premature failure (Dalessandri et al., 2014) Citeria of Success TADs (Sharma et al., 2011)
Mininum value:0% Maximum value: 100% Higher value indicate higher percentage of TADs that remain functionally stable and serve their orthodontic purpose throughout treatment, without mobility, infection, or premature failure |
at immediate post-insertion (Day 0), post alignment (at the start of en-masse retraction), and subsequently at monthly intervals during en-masse retraction: Month 1, Month 2, Month 3, Month 4, Month 5, and Month 6.
|
|
Primary stability and secondary stability
Time Frame: at immediate post-insertion (Day 0), post alignment (at the start of en-masse retraction), and subsequently at monthly intervals during en-masse retraction: Month 1, Month 2, Month 3, Month 4, Month 5, and Month 6.
|
Primary stability Mechanical retention of a TAD immediately after placement, derived from the mechanical interlocking between the screw threads and the surrounding bone (Seifi & Matini, 2016) Secondary stability Biological stabilisation of a TAD that occurs after healing and remodelling, primarily due to bone apposition and osseointegration around the device (Wu et al., 2021) AnyCheck Implant Stability Meter (Figure 3.8) to determine stability of TADs by measuring implant Stability Test (iST) value at insertion T0 to T9. Min value: 1 Max value: 99 Higher value indicate high stability of TADs Interpretation of iST (Kim et al., 2020) IST Range Interpretation <60 Low primary stability 60-64 Moderate stability >64 High stability |
at immediate post-insertion (Day 0), post alignment (at the start of en-masse retraction), and subsequently at monthly intervals during en-masse retraction: Month 1, Month 2, Month 3, Month 4, Month 5, and Month 6.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Patient- reported outcome
Time Frame: at immediate post-insertion (Day 0), post alignment (at the start of en-masse retraction), and subsequently at monthly intervals during en-masse retraction: Month 1, Month 2, Month 3, Month 4, Month 5, and Month 6.
|
Patient perception of pain at each quadrant (upper right, upper left, lower right, and lower left jaw) will be measured with a four-point Likert scale correlated with a 10-point Visual Analogue Scale (VAS). Perceptions of swelling, chewing difficulty, and cleaning difficulty at each jaw quadrant will be captured using categorical dichotomous responses (Yes or No). Patient reported outcome questionnaires (Appendix 2): Patient perception of pain 0: No pain/VAS 0)
|
at immediate post-insertion (Day 0), post alignment (at the start of en-masse retraction), and subsequently at monthly intervals during en-masse retraction: Month 1, Month 2, Month 3, Month 4, Month 5, and Month 6.
|
|
Trabecular bone volume fraction (BV/TV)
Time Frame: During enmasse retraction at Month 6
|
Percentage of the volume of mineralized trabecular bone (bone volume, BV) to the total volume (TV) of the region of interest within cancellous bone. Association between maxillary and mandibular trabeculae bone volume fraction with TADs stability, survival and success White region: (Bruker, 2013) Solid regions of the bony trabeculae areas within the range of the binary threshold selection Black region: Spaces among the bong mandibular trabeculae Min value: 1% Max value: 99% Higher value indicate higher percentage of the volume of mineralized trabecular bone (bone volume, BV) to the total volume (TV) of the region of interest within cancellous bone. ercentage of the volume of mineralized trabecular bone (bone volume, BV) to the total volume (TV) of the region of interest within cancellous bone. |
During enmasse retraction at Month 6
|
|
Complications (inflammation, mobility, or need for replacement)
Time Frame: at immediate post-insertion (Day 0), post alignment (at the start of en-masse retraction), and subsequently at monthly intervals during en-masse retraction: Month 1, Month 2, Month 3, Month 4, Month 5, and Month 6.
|
Need for replacement Yes: Need replacement of TADs (IST < 60) No: No need replacement of TADs (IST > 60) |
at immediate post-insertion (Day 0), post alignment (at the start of en-masse retraction), and subsequently at monthly intervals during en-masse retraction: Month 1, Month 2, Month 3, Month 4, Month 5, and Month 6.
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- DF CD2615/0058(P)
- UMG-2026 (Other Grant/Funding Number: Universiti Malaya)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Bimaxillary Protrusion
-
Future University in EgyptCompleted
-
Future University in EgyptCompletedBimaxillary ProtrusionEgypt
-
Future University in EgyptCompletedBimaxillary ProtrusionEgypt
-
Cairo UniversityUnknownBimaxillary ProtrusionEgypt
-
Cairo UniversityCompletedBimaxillary ProtrusionEgypt
-
Future University in EgyptActive, not recruitingBimaxillary ProtrusionEgypt
-
Future University in EgyptActive, not recruitingBimaxillary ProtrusionEgypt
-
Future University in EgyptCompletedBimaxillary ProtrusionEgypt
-
Cairo UniversityUnknownEn-masse Retraction , Class I Bimaxillary Protrusion
-
Mansoura UniversityActive, not recruiting
Clinical Trials on Temporary Anchorage Device (TAD)
-
Alexandria UniversityCompletedInferior Alveolar Nerve InjuriesEgypt
-
Hospital of the Ministry of Interior, Kielce, PolandCompleted
-
Faculty of Dental Medicine for GirlsEnrolling by invitationAnterior Openbite MalocclusionEgypt
-
University of British ColumbiaTerminated
-
University of AarhusOdense University Hospital; Aarhus University Hospital; CHU de Quebec-Universite... and other collaboratorsCompletedNeuralgia | Spinal Cord StimulationDenmark, Sweden, Belgium, Canada, Germany, Netherlands
-
Medi-Tate Ltd.CompletedBenign Prostate Hyperplasia | Bladder Neck ObstructionIsrael
-
Region GävleborgMalmö University; Swedish Dental Associations Scientific Funds; Department of... and other collaboratorsCompletedOrthodontic Anchorage Procedures | Orthodontic Space ClosureSweden
-
Medical College of WisconsinUniversity of Pennsylvania; Abiomed Inc.CompletedCardiogenic Shock | Peripartum CardiomyopathyUnited States
-
University of California, DavisUniversity of California, San DiegoTerminatedLVAD (Left Ventricular Assist Device) Driveline InfectionUnited States